Stock Research: Bristol-Myers Squibb

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Bristol-Myers Squibb

NYQ:BMY US1101221083
50
  • Value
    94
  • Growth
    42
  • Safety
    Safety
    50
  • Combined
    62
  • Sentiment
    25
  • 360° View
    360° View
    50
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases. It operates in oncology, hematology, immunology, and neuroscience. The company operates globally. In the last fiscal year, the company had a market cap of $94,489 million, profits of $36,351 million, revenue of $48,300 million, and 34,100 employees.

more

ANALYSIS: With an Obermatt 360° View of 50 (better than 50% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bristol-Myers Squibb are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Bristol-Myers Squibb. The consolidated Value Rank has an attractive rank of 94, which means that the share price of Bristol-Myers Squibb is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 94% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 50. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 25. Professional investors are more confident in 75% other stocks. The consolidated Growth Rank also has a low rank of 42, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 58 of its competitors have better growth. ...read more

more
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
94 92 92 97
Growth
42 43 7 27
Safety
Safety
50 30 31 35
Sentiment
25 40 68 51
360° View
360° View
50 51 39 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
7 9 10 34
Opinions Change
50 12 48 64
Pro Holdings
n/a 88 87 40
Market Pulse
7 79 78 68
Sentiment
25 40 68 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
94 92 92 97
Growth
42 43 7 27
Safety Safety
50 30 31 35
Combined
62 58 29 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
76 43 37 40
Price vs. Earnings (P/E)
24 83 91 96
Price vs. Book (P/B)
40 23 19 35
Dividend Yield
97 98 98 98
Value
94 92 92 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
34 6 25 11
Profit Growth
92 100 31 47
Capital Growth
10 17 26 48
Stock Returns
38 61 37 73
Growth
42 43 7 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
17 16 24 34
Refinancing
68 27 25 25
Liquidity
76 75 76 66
Safety Safety
50 30 31 35

Similar Stocks

Discover high‑ranked alternatives to Bristol-Myers Squibb and broaden your portfolio horizons.

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock is a good value with safe financing, but has low growth and negative sentiment. It is a good option for a cautious value investor looking for stability but who can tolerate low momentum and skeptical professional opinion.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: